In a double-blind (DB), placebo-controlled (PC) trial, 32 healthy adults consumed either one 15 mg capsule of PreforPro or placebo daily, for 28 days. At the end of the study, those taking PreforPro had significantly fewer problematic flora relative to the placebo, including one mapping to Clostridium perfringens, an undesirable flora. This microbe was reduced by as much as 75% by ingestion of PreforPro. Two other markers representing Eubacterium species, species known to be beneficial to metabolic health, were increased 4-5 fold after PreforPro consumption, compared to the placebo. Interleukin-4, a biomarker of inflammation, was also significantly reduced from baseline after PreforPro consumption.

Another DB, PC trial of similar size and duration demonstrated a positive change in a liver biomarker, aspartate aminotransferase, with prebiotic consumption. The results of both of these studies demonstrate the benefits PreforPro can have on balancing the microbiome in the digestive system, thereby supporting a reduction in occasional digestive symptoms and supporting a better balanced immune response.

In a 4-week, randomized, double-blind, placebo-controlled trial, 66 healthy adult participants consumed either placebo, Bifidobacterium lactis BL04, or Bifidobacterium lactis BL04 + PreforPro. Gastrointestinal health questionnaire scores exhibited a significant positive effect in gastrointestinal symptoms with the B. lactis BL04 + PreforPro group, including stool consistency. There was a trending improvement in colon comfort as well. The PreforPro + B. lactis group exhibited the greatest percentage (24%) of subjects with overall improvements to their GI health. Lachnobacterium and Lactobacillus species increased with both B. lactis groups. A larger increase in Lactobacillus was observed in the B. lactis BL04 + PreforPro group compared to BL04 alone. Other increases in beneficial microbial taxa were observed in the PreforPro group, as well as decreases in non-beneficial species including Citrobacter and Desulfovibrio.

In the 28-day double-blinded, placebo-controlled trial with 32 subjects, gut microbiota levels were analyzed. After prebiotic consumption, E. coli levels were significantly reduced. The same was not observed with the placebo group. On average, the number of E.coli reads were reduced ~ 40% with the prebiotic bacteriophage blend vs ~ 14% with placebo. Since E. coli located in the bowel and stool act as a reservoir for urinary tract imbalances, a reduction of this species in the gut has been shown to have a beneficial effect on urinary tract health, in general.